Oral contraceptives (birth-control pills) are used to prevent pregnancy. Combinations of estrogen and progestin (two female sex hormones) or progestin only work by preventing ovulation (the release of eggs from the ovaries). Combinations of estrogen and progestin prevent pregnancy by inhibiting the release of luteinizing hormone (LH) and follicle stimulating hormone (FSH) from the pituitary gland in the brain. Oral contraceptive pills are used to prevent pregnancy. United Nations reported increased percentage of married women who use at least one method of contraception from 55% in 1990 to 63% in 2010. Factors such as high incidence rate of unintended pregnancies, unmet contraceptive needs, rising awareness initiatives by governments and NGOs, implementation of the Affordable Care Act, increasing maternal age and late pregnancies along with family planning initiatives are driving the growth of the global oral contraceptive pills market.
The global oral contraceptive pills market report estimates the market size (Revenue US$ million – 2014 to 2021) for key market segments based on the drug (pill) type (combination drugs – monophasic, triphasic; progestin only, etc.), drug categories (branded and generic), and forecasts growth trends (CAGR% – 2017 to 2021).
The global oral contraceptive pills market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global oral contraceptive pills market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.
Major players operating in the global oral contraceptive pills market and included in this report are Allergan plc, Bayer AG, Janssen Global Services, Merck & Co., Inc., and Teva Pharmaceutical Industries Ltd.